CareDx, Inc.

How big is CareDx, Inc.?

As of Jun 18, CareDx, Inc. has a market capitalization of $1.09 billion, with net sales of $346.42 million and a net profit of $68.55 million over the latest four quarters.

As of Jun 18, CareDx, Inc. has a market capitalization of 1,086.88 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 346.42 million, while the sum of Net Profit for the same period is 68.55 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 378.43 million and Total Assets of 505.46 million.

What does CareDx, Inc. do?

CareDx, Inc. is a molecular diagnostics company specializing in diagnostic surveillance solutions for transplant patients, with recent net sales of $85 million and a market cap of approximately $1.09 billion. The company reported a net profit loss of $10 million as of March 2025.

Overview:<BR>CareDx, Inc. is a molecular diagnostics company focused on developing and commercializing diagnostic surveillance solutions for transplant patients, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 85 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,086.88 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: -4.89% <BR>Price to Book: 2.87<BR><BR>Contact Details:<BR>Address: 1 Tower Place, 9Th Floor, SOUTH SAN FRANCISCO CA : 94080 <BR>Tel: ['1 415 2872300', '1 646 2771266'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.caredx.com/

Should I buy, sell or hold CareDx, Inc.?

Who are in the management team of CareDx, Inc.?

As of March 2022, the management team of CareDx, Inc. includes Dr. Peter Maag (Executive Chairman), Dr. Reginald Seeto (CEO), and several independent directors, including Mr. Michael Goldberg, Mr. George Bickerstaff, Dr. Frederick Cohen, Dr. Grace Colon, and Ms. Christine Cournoyer. They collectively guide the company's strategic direction.

As of March 2022, the management team of CareDx, Inc. includes the following individuals:<BR><BR>- Dr. Peter Maag, who serves as the Executive Chairman of the Board of Directors.<BR>- Dr. Reginald Seeto, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Michael Goldberg, who holds the position of Lead Independent Director.<BR>- Mr. George Bickerstaff, who is an Independent Director.<BR>- Dr. Frederick Cohen, who also serves as an Independent Director.<BR>- Dr. Grace Colon, who is another Independent Director.<BR>- Ms. Christine Cournoyer, who is an Independent Director as well.<BR><BR>In summary, the management team consists of key executives and independent directors who guide the strategic direction of CareDx, Inc.

Is CareDx, Inc. technically bullish or bearish?

As of September 2, 2025, CareDx, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 with a 1-year return of -49.52% compared to its 17.14%.

As of 2 September 2025, the technical trend for CareDx, Inc. has changed from mildly bearish to bearish. The overall stance is bearish with weak strength indicated by the MACD being bearish on a monthly basis and the KST also showing bearish signals. While the weekly MACD and RSI are mildly bullish and bullish respectively, the moving averages and Bollinger Bands indicate a mildly bearish trend on both weekly and monthly timeframes. Additionally, the Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. <BR><BR>In terms of performance, CareDx has underperformed against the S&P 500 over the year and longer periods, with a 1-year return of -49.52% compared to the S&P 500's 17.14%.

Is CareDx, Inc. overvalued or undervalued?

As of October 17, 2025, CareDx, Inc. is considered very attractive and undervalued despite negative earnings, with a Price to Book Value of 2.87 and an EV to Sales ratio of 2.49, while its stock has significantly underperformed compared to the S&P 500.

As of 17 October 2025, the valuation grade for CareDx, Inc. has moved from fair to very attractive, indicating a significant improvement in its perceived value. Based on the available metrics, CareDx appears to be undervalued, especially considering its Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, despite its negative earnings metrics. The company’s EV to Sales ratio stands at 2.49, which suggests a reasonable valuation relative to its sales, particularly when compared to peers like Organogenesis Holdings, Inc. with a P/E of 608.59 and Castle Biosciences, Inc. with an EV to EBITDA of -71.36.<BR><BR>In terms of stock performance, CareDx has faced substantial declines, with a year-to-date return of -32.70% compared to the S&P 500's 13.30%, and a five-year return of -72.05% against the S&P 500's 91.29%. This stark contrast reinforces the notion that CareDx may be undervalued, as its current price does not reflect its potential relative to its industry peers.